Exploring Future Avenues of Growth for Psychosocial Cancer Care

News
Video

“Psycho-oncology has made remarkable progress; however, there are still critical areas for further development,” Cristiane D. Bergerot, PhD, BS, MS, said.

Psychosocial care needs to be treated as an integral part of standard care in cancer treatment, not as an optional service, Cristiane Decat Bergerot, PhD, BS, MS, stated.

When prompted about the way she’d like to see the field of psycho-oncology grow, Bergerot spoke about accessibility, advocacy efforts, and telehealth. In the modern age, with readily available access to technology, telehealth approaches have become more prevalent for psychosocial care.

For example, a study presented at the 2025 American Psychosocial Oncology Society Meeting showed that telehealth intervention support groups were effective and viable as a strategy for adolescents and young adults with cancer.1

Of 18 patients who completed the acceptability measure, 78% strongly agreed that they would recommend the telehealth group. Additionally, 39% reported feeling very satisfied with their experience in the telehealth group, with 44% feeling satisfied and 17% feeling somewhat satisfied.

CancerNetwork® spoke with Bergerot, the head of supportive care at Grupo Oncoclinicas in Brazil, and a member of the International Psycho-Oncology Society (IPOS), after the announcement of the first ever World Psycho-Oncology Day on April 9, 2025, by IPOS.2

Transcript:

Psycho-oncology has made remarkable progress; however, there are still critical areas for further development. While [psychosocial care is] increasingly recognized, it should be fully integrated into standard care, rather than treated as an optional service because we need to expand access to psycho-oncology to ensure that all patients receive the support they need. Advocacy efforts must also continue to push for the inclusion of psychosocial care in national and global cancer care policies. At the same time, the growing adoptions of telehealth present new opportunities to make psycho-oncology service more accessible and break down many of the barriers to care. Additionally, ongoing research into the effectiveness of various interventions, from digital solutions to community-based programs, will help refine best practices and reinforce the importance of psycho-oncology within healthcare systems.

References

  1. Chan S, Patten J, Lau N. Telehealth group intervention for adolescents and young adults with cancer: a feasibility pilot study. Presented at the 2025 American Psychosocial Oncology Society Meeting; March 5-7, 2025, Pittsburgh, PA. Poster W2.
  2. World Psycho-Oncology Day (WPOD). IPOS. Accessed April 2, 2025. https://tinyurl.com/43c9rr2c
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
Related Content